Medigene AG Sustainability Reports
Medigene AG is an immuno-oncology platform company that specializes in developing T cell receptor-engineered T cell (TCR-T) therapies to eliminate cancer. The company is currently undergoing insolvency proceedings and the liquidation of its remaining assets.
Sector: Manufacturing
Country: Germany
Exchange: Börse Frankfurt
LEI: 391200I33JD2DKZGDX06
FIGI: BBG001SFH9C2
6 reports from 2009 to 2023